Page last updated: 2024-12-07

rhein-9-anthrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rhein-9-anthrone: metabolite of sennosides A+B formed in the colon; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119396
CHEMBL ID421615
CHEBI ID174546
SCHEMBL ID12774642
MeSH IDM0157045

Synonyms (27)

Synonym
4,5-dihydroxy-10-oxo-9,10-dihydroanthracene-2-carboxylic acid
CHEBI:174546
NCI60_020625
nsc-658580
rheinanthrone
2-anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-10-oxo-
rhein-9-anthrone
nsc658580
4,5-dihydroxy-10-oxo-9h-anthracene-2-carboxylic acid
480-09-1
CHEMBL421615 ,
bdbm50060855
4,5-dihydroxy-10-oxo-9,10-dihydro-anthracene-2-carboxylic acid
unii-0yqk3wbh32
nsc 658580
4,5-dihydroxy-10-oxo-9,10-dihydro-2-anthracenecarboxylic acid
0yqk3wbh32 ,
2-anthracenecarboxylicacid, 9,10-dihydro-4,5-dihydroxy-10-oxo-
SCHEMBL12774642
DTXSID10197374
9,10-dihydro-4,5-dihydroxy-10-oxo-2-anthroic acid, 8ci
DB13175
monorheinanthron
1,8-dihydroxy-9-anthrone-3-carboxylic acid
2-anthroic acid, 9,10-dihydro-4,5-dihydroxy-10-oxo-
9,10-dihydro-4,5-dihydroxy-10-oxo-2-anthracenecarboxylic acid
Q16888506
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthracenesCompounds containing an anthracene skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-lipoxygenase Bos taurus (cattle)IC50 (µMol)3.00000.18001.75824.0000AID160507
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID233179Antioxidant potential was assessed from reducing activity against 2,2,di-phenyl-1-picrylhydrazyl.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID85482Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID19630Partition coefficient (logP)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID231071Peroxidant property was expressed as ratio of uMol of malondialdehyde and mMol of deoxyribose released by 75 uM test compound1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID1605075-LO inhibitory activity was determined by inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes (PMNL)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (18.18)18.7374
1990's16 (72.73)18.2507
2000's0 (0.00)29.6817
2010's2 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.58 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]